Dr. Mirko Essing

#News: Roche (ROG.S),  on Thursday raised its full-year earnings forecast after exceeding expectations for the first half, driven by strong demand for newer drugs such as #eyemedicine #Vabysmo. The Swiss drugmaker said it expects growth in adjusted earnings in the "high single-digit range", excluding the effect of currency swings and resolution of tax disputes in 2023, up from previous estimates of "mid single-digit" percentage growth. Shares were up 2.4% in morning trading, after earlier rising as much as 4% to a one-year high. First-half adjusted operating profit gained 4% to 11.3 billion Swiss francs ($12.8 billion), the family-controlled drugmaker said on Thursday, beating analysts' consensus estimate of 10.5 billion, based on LSEG data. Read more from Reuters 👇🏼

3

Last moments at Basel for the Swiss Biotech Days 2024! The health system is moving forward thanks to innovations in research, data, and AI. Great discussions and connections from different players in the field. Let’s keep in touch and wish the best success to new emerging biotech companies! #SwissBiotech #SwissBiotechDay

136

2 Kommentare

#News: Bayer and Evotec have updated the focus of their strategic collaboration to develop #precisiontreatments for #cardiovasculardiseases (CVDs). Financial terms were not disclosed.   The collaboration aims to identify and validate #noveltargets, with the goal of building a portfolio of precision #cardiologytherapeutics by leveraging #Evotec's disease modelling capabilities using human #inducedpluripotentstemcells (iPSCs). #iPSCs provide unique opportunities to identify new disease mechanisms and pathways for novel treatments. Under the terms of the agreement, both companies will contribute drug targets and a comprehensive set of high-quality technology platforms.   Bayer and Evotec will share responsibilities during the preclinical development of potential clinical candidates. Bayer will be responsible for any subsequent clinical development and commercialization.   “This development takes our long-standing collaboration with Evotec to a new level, and has the added benefit of lessons learned from working together the past 12 years,” said Juergen Eckhardt, M.D., Head of Business Development & Licensing at Bayer’s Pharmaceuticals Division. “We remain committed to develop innovative therapies for patients in need and to tackle the high burden of cardiovascular disease.”
 Read more from Contract Pharma 👇🏼

4

In healthcare, collaborations often bring revolutions. Exciting news in women's health comes from the Swiss duo ASPIVIX and Bayer (Schweiz). They've joined forces to present Carevix, an innovative cervical stabiliser, shaking up the world of gynaecology. Carevix shines as a beacon for comfort, touting a CE Mark for its ability to make transcervical procedures, like IUD placements, less daunting. This partnership marries Bayer's contraceptive expertise with ASPIVIX's vision for gynaecological advancements. Together, they're tackling the challenge of painful IUD insertions head-on, improving experiences for countless women. It's big news when a new device promises to ease a common pain point for millions. Carevix is set to replace the outdated tenaculum with a gentler approach that has shown to lessen both pain and bleeding. This technology aligns perfectly with today's healthcare standards, focusing not just on effectiveness but also on patient comfort. #WomensHealth #Innovation #Carevix

1

Breaking ground in Oncology: Europe's Next Chapter 🌍💡 In an unprecedented move, leading pharmaceutical giants are gearing up for a series of large-scale clinical trials in oncology across Europe. With innovative therapies on the horizon, the focus is sharpening on the critical role of staffing to ensure these trials succeed. Groundbreaking research promises not just hope, but real change. From targeted therapies to immunotherapies, these trials could redefine cancer treatment as we know it. As each phase demands precision and expert knowledge, the need for top-tier clinical researchers, data analysts, and medical professionals is at its peak. Europe stands at the forefront of this endeavour, and it's our shared mission to see it thrive. We're talking cutting-edge science meeting top talent to transform lives. Join the conversation - what's your take on Europe's potential to lead the next wave of oncology breakthroughs? #OncologyInnovation #ClinicalTrials #PharmaCareers #HRS #Science

8

Is your role becoming more involved with AI? If so you should be at this session to familiarise yourself with what the EU AI act has to say.

5

The overall picture of the Swiss biotech industry is quite positive. The Swiss Biotech Report recently published provides an analysis of the 2023 biotech funding as well as other key ratios and statistics: https://lnkd.in/dGSvh2d With Swiss Biotech Association https://lnkd.in/dAtS7hyU

152

The European Society of Hypertension Annual Conference is underway in Berlin! Sharing the latest advances in innovation and research at conferences like ESH is crucial to addressing unmet needs and driving progress in hypertension. Resistant and uncontrolled hypertension are significant contributors to cardiovascular and renal complications that affect millions of people worldwide. The limitations of current treatment options mean there is an urgent need for alternatives to improve outcomes. Aldosterone is an important driver of hypertension and cardiorenal outcomes. Read more about aldosterone and the work we are doing to uncover novel approaches to slowing disease progression in hypertension here: https://lnkd.in/eRH38DA3  #ESH2024 #Hypertension #ClinicalInnovation #WhatScienceCanDo 

82

1 Kommentar

The report of the 2nd listen and learn focus group meeting of the Quality Innovation Group (QIG), EMA, is now published. It includes a contribution from the #Inno4Vac project on transforming CFD to compartment models, and on the coupling between compartment models and kinetic models!

33

Thank you to #BakerMcKenzie, #Stifel, and #IQVIA for inviting me to an inspiring panel discussion on the Future of Dealmaking in Biotech. We delved deep into the impact of the newly adopted first Implementation Act on EU HTAR. It's clear that Health Technology Developers and European Union Member States are embarking on a challenging journey, but one with the vital goal of accelerating equitable access to healthcare across Europe. A thought-provoking question from the audience stood out: “With all these changes and increasing complexities in the EU regulatory environment, why should companies consider investing in Europe and bringing new healthcare innovation?” Here's why: 💠 European Union and EFTA are home to >460million people. 💠 Current and future patients are eagerly waiting for healthcare innovations to improve and/or prolong their lives. 💠 We have Universal Healthcare Coverage, ensuring equity in access regardless of economic status. I’m fortunate to work at a company, where this question has never occurred. #BeiGene champions the belief that all patients, no matter where they live, deserve access to impactful cancer treatments. Cancer has no borders, neither do we. This belief is why I joined BeiGene, and it's fulfilling to see us living up to this promise every day. 💚 Together, let's make healthcare innovation borderless!💚 #BeiGene #HealthcareInnovation #Biotech #EquitableAccess #GPL #UniversalHealthcare 

56

1 Kommentar

Under the motto "Seed and Succeed 🌱," BIOTECH AUSTRIA invited to its 3rd Biotech Circle Austria at the Wiener Boerse this morning. Norbert Bischofberger delivered an inspiring talk, addressing the disparities between the biotech funding landscape in the US and Europe, followed by a lively panel discussion, with some thought-provoking questions. 𝘋𝘰 𝘸𝘦 𝘴𝘰𝘸 𝘴𝘦𝘦𝘥𝘴 𝘴𝘶𝘤𝘤𝘦𝘴𝘴𝘧𝘶𝘭𝘭𝘺 𝘣𝘶𝘵 𝘧𝘢𝘪𝘭 𝘵𝘰 𝘴𝘶𝘤𝘤𝘦𝘦𝘥? 𝘐𝘴 𝘴𝘤𝘪𝘦𝘯𝘤𝘦 𝘪𝘯 𝘈𝘶𝘴𝘵𝘳𝘪𝘢 𝘮𝘦𝘳𝘦𝘭𝘺 "𝘨𝘰𝘰𝘥" 𝘳𝘢𝘵𝘩𝘦𝘳 𝘵𝘩𝘢𝘯 "𝘨𝘳𝘦𝘢𝘵"? I believe that we have fantastic scientific achievements 🔬 and success stories in Austria, yet perhaps we sometimes lack the confidence(?) to effectively communicate them to a wider audience. Let’s dare to be a little bit bolder, think bigger, and also embrace failures without fear. We can only truly convince others of Austria being a great place for biotech when we are convinced ourselves! Thank you, BIOTECH AUSTRIA for organizing such a great event! #BCA2024 #BiotechAustria #Science

38

The Swiss Biotech Day event has just ended. I wanted to share some thoughts after very interesting conversations and talks. 🖥️ It's simply amazing to see AI revolutionising the pharma and biotech industries, from drug development to clinical trial optimisation. 🧬 Biologics, such as ADCs, nanoparticles (such as exosomes and viral vectors) and cell therapies are sparking conversations for their role, especially in cancer treatments. The potential is thrilling! 🤶 Rejuvenation is marking a new frontier for therapeutic innovation. 💊 The impact of Annex 1 is undeniable, leading to major restructuring for some CDMOs to stay ahead. 💡 Start-up pitches? Pure dynamism and creativity! 💰 Finally, witnessing the strategic investments flowing into Switzerland was a highlight. Multicultural, innovative, government support are the main drivers for investors to look into Swiss companies. #SwissBiotechDay #BiotechInnovation #InvestmentTrends #GlobalBiotech

19

Slides from the recent keynote "Biopharma Dealmaking: Time for a Re-Think" I delivered at the Swiss Healthcare Licensing Group meeting in Montreux in May are now available on the Lumanity website. https://lnkd.in/ePi9Vwse This data rich presentation is important viewing for anyone involved with or interested in biotech corp dev strategy but especially for those pre-commercial biotech "sellers" pinning their hopes on a large pharma partnership. The historically unprecedented increase in the number of biotechs reaching or surpassing clinical PoC stage (5 x or greater over past decade) coupled with a limited number of large pharma "buyers" means odds for vast majority of would be sellers are long. Many more of these biotechs should start to see self-commercializing, especially those pursuing advanced therapeutic modalities, such as cell and gene therapy, as more of a "Plan A" than B. And for many of these companies the time to get started is now, not when they are late in P3 or beyond.

64

31 Kommentare

Viral Vectors in Gene Therapy: Where Do We Stand in 2023? In summary, viral vectors have been successfully applied for a broad spectrum of disease indications. Encouraging results have been obtained in preclinical studies in animal models, and also in clinical trials in patient groups with long-lasting cure, confirmed especially in SCID-X1 patients. Gendicine TM , a replication-deficient Ad vector expressing the p53 gene, was approved in China, and more than 30,000 patients with head and neck cancer have been treated with it. Gendicine TM  has demonstrated good safety and efficacy, especially in combination with chemo- and radiotherapy. In the US and Europe, a second-generation oncolytic HSV vector expressing GM-CSF has been approved for melanoma therapy. The AAV-based Onasemnogene aboparvovec (Zolgensma) has been approved for the treatment of SMA. Furthermore, approval for the AAV-based Voretigene neparvovec (Luxturna) was received for the treatment of inherited retinal dystrophy. As mentioned above, several Ad-based COVID-19 vaccines have been granted EUA, and the Ebola vaccine Ervebo has been approved. However, it is important to keep in mind the case of Glybera TM , the AAV-based treatment of lipoprotein lipase deficiency. Despite its approval in Europe, the clinical use of Glybera TM  was discontinued due to lack of demand for this rare monogenic inherited disease.

184

5 Kommentare

CHANGE4RARE 2025 AGENDA PUBLISHED The #change4RARE 2025 agenda, developed in collaboration with key rare disease experts, proposes concrete measures in the political and governmental arenas to improve conditions for people with rare diseases. The 4 core messages included in the 2025 Agenda are summarized in the Pharma Fakten article below: 1.     Strengthen patient participation 2.     Collect and use data systematically 3.     Invest in infrastructure 4.     Ensure market access for orphan drugs   You can read and download the complete Agenda 2025 here: https://lnkd.in/enfUdav7

18

AbbVie reported $12.3 billion in revenues for Q1 2024, which represents less than 1% year-on-year growth. Here is my visual breakdown of their earnings: 💊 AbbVie’s immunology portfolio was its biggest revenue driver, which includes top-seller Humira. However, Humira's worldwide sales fell by 36% as it faces biosimilar competition. This decline was partially offset by the strong growth of its newer drugs, Skyrizi and Rinvoq. 🚀 Counteracting the reduced revenues of its immunology segment, the firm is diversifying its portfolio. This saw its oncology and neuroscience sectors with encouraging growth of 9% and 16%, respectively. 🤝 AbbVie has also completed its acquisition of ImmunoGen, a move that will help strengthen its position in the oncology market.

8

1 Kommentar